ライフサイエンスコーパス: fatty acid-binding protein

1 nine, aspartate transaminase, and heart-type fatty acid binding protein).

2 ro-brain natriuretic peptide, and heart-type fatty acid binding protein).

3 ts confirm the function of this protein as a fatty acid binding protein.

4 sis, but this was not seen in the absence of fatty acid binding protein.

5 gh recently it was proposed to function as a fatty acid binding protein.

6 raction, we coexpressed S100A7 and epidermal fatty acid binding protein.

7 tubulin beta 2 A, histone H2B and brain type fatty acid binding protein.

8 tiation, alkaline phosphatase and intestinal fatty acid binding protein.

9 aperone proteins, regulatory proteins, and a fatty acid-binding protein.

10 4) (Ki = 33 (+/-2) nM) bound to keratinocyte fatty acid-binding protein.

11 xpress the differentiation marker intestinal fatty acid-binding protein.

12 oxidized low density lipoprotein, and aP2, a fatty acid-binding protein.

13 pocalin, kidney injury molecule 1, and liver fatty acid-binding protein.

14 ntration and its correlation with intestinal fatty acid-binding protein.

15 ugs, including icosapent ethyl and adipocyte fatty-acid-binding protein.

16 ies and a structural motif characteristic of fatty acid binding proteins.

17 lar to the mammalian family of intracellular fatty acid binding proteins.

18 sors, thyroid function-related proteins, and fatty acid binding proteins.

19 functions are redundant with those of other fatty acid-binding proteins.

20 the same critical functions in all bacterial fatty acid-binding proteins.

21 he mean methylation of 1444 genes, including fatty acid binding protein 1 (FABP1), fatty acid binding

22 ein 1 (1.35), C-C motif chemokine 20 (1.35), fatty acid-binding protein (1.33), tumor necrosis factor

23 Fatty acid binding protein-1 (FABP-1), which is protecti

24 , cystatin-C, beta2-microglobulin, and liver fatty acid binding protein-1) to healthy volunteer level

25 mational fluctuations of unfolded intestinal fatty acid binding protein (131 aa, 15 kDa) by using flu

26 luding fatty acid binding protein 1 (FABP1), fatty acid binding protein 2 (FABP2), melanocortin 2 rec

27 or-1 being increased, no change to adipocyte fatty acid binding protein 2 and suppression of CD36.

28 unctional missense mutation [Ala54Thr of the fatty acid-binding protein 2 gene (FABP2)] has previousl

29 R-1 were used to demonstrate that heart-type fatty acid-binding protein-3 (FABP3) is a target of miR-

30 Fatty acid binding protein 4 (FABP4 or aP2) is an intrac

31 the functional properties of the cytoplasmic fatty acid binding protein 4 (FABP4) has advanced with t

32 pt levels of PPARG and the PPARG target gene fatty acid binding protein 4 (FABP4) in pbASCs.

33 Fatty acid binding protein 4 (FABP4) is a fatty acid cha

34 Fatty acid binding protein 4 (FABP4) plays an important

35 The fatty acid binding protein 4 (FABP4), commonly known as

36 Fatty acid binding protein 4 (FABP4, also known as aP2)

37 t and rapid suppression of the expression of fatty acid binding protein 4 and peroxisome proliferator

38 f bone sialoprotein, lipoprotein lipase, and fatty acid binding protein 4 are the preferred markers f

39 s of reduced lipolysis and lower circulating fatty acid binding protein 4 levels.

40 d expression of UCP1 when expressed from the fatty acid binding protein 4 promoter, even when mice ar

41 pose Grp78-knockout mouse utilizing the aP2 (fatty acid binding protein 4) promoter-driven Cre-recomb

42 ne-sensitive lipase, lipoprotein lipase, and fatty acid binding protein 4) versus sham.

43 A expression of the differentiation markers; fatty acid binding protein 4, peroxisome proliferator-ac

44 upporting genes (e.g., SP7 [osterix], FABP4 [fatty acid binding protein 4], ANGPT1 [angiopoietin 1],

45 Fatty acid-binding protein 4 (FABP4 or aP2 in mice) has

46 Fatty acid-binding protein 4 (FABP4) delivers ligands fr

47 Fatty acid-binding protein 4 (FABP4) is an adipogenic pr

48 and expression of C/EBPalpha, PPARgamma and fatty acid-binding protein 4 (FABP4).

49 diminishing binding to its downstream target fatty acid-binding protein 4 (FABP4).

50 A protein array identified upregulation of fatty acid-binding protein 4 (FABP4, also known as aP2)

51 dipogenesis, and also its downstream target, fatty acid-binding protein 4 (FABP4/aP2).

52 Fenugreek decreased hepatic expression of fatty acid-binding protein 4 and increased subcutaneous

53 a, CCAAT/enhancer-binding protein alpha, and fatty acid-binding protein 4 expression in mouse embryon

54 tagonist [IL-1ra], hepatocyte growth factor, fatty acid-binding protein 4, and tissue plasminogen act

55 d protein expression of an adipocyte marker, fatty acid-binding protein 4, by 5-fold.

56 ey lipid binding protein adipocyte protein 2/fatty acid-binding protein 4.

57 ed a short-hairpin RNA (shRNA) for silencing fatty-acid-binding protein 4 (shFABP4), a key lipid chap

58 ptake and intracellular transport, including fatty-acid-binding proteins 4 and 5 (FABP4 and FABP5).

59 In addition, we report that fatty acid binding protein-4 (FABP4) messenger RNA is up

60 heparin-binding EGF-like growth factor, and fatty acid binding protein-4-had been previously describ

61 death in macrophages and prevents macrophage fatty acid-binding protein-4 (aP2) expression.

62 Downregulated genes included fatty acid binding protein 5, cyclin D1, and some signal

63 ar retinoic acid binding protein 2 (CRABP2), fatty acid-binding protein 5 (FABP5), retinoic acid rece

64 e, correlates with a marked up-regulation of fatty acid-binding protein 5 (FABP5).

65 designed an shRNA construct to mouse fabp5 (fatty acid-binding protein 5).

66 Collagen type Ialpha, fatty-acid-binding-protein 5, nidogen-1, cartilage oligo

67 key pro-neural/neuronal factors, CSDE1 binds fatty acid binding protein 7 (FABP7) and vimentin (VIM)

68 its binding target by proteomic analysis as fatty acid binding protein 7 (FABP7), also known as brai

69 chemokine (C-X-C) motif ligand 12 (Cxcl12), fatty acid binding protein 7 (Fabp7), plasma membrane pr

70 heir lineage myelin protein zero (P0) and/or fatty acid binding protein 7 (Fabp7).

71 eration of mono-unsaturated fatty acids, and fatty acid-binding protein 7, a regulator of glioma stem

72 Fatty acid-binding protein-7 (FABP7) has been shown to b

73 The male germ cell-specific fatty acid-binding protein 9 (FABP9/PERF15) is the major

74 Here, we identify adipocyte-type fatty acid-binding protein (A-Fabp) and other members of

75 The adipocyte and heart fatty acid-binding proteins (A- and HFABP) are members o

76 l abnormalities, plasma levels of intestinal fatty acid binding protein, a marker of enterocyte turno

77 Perfusate levels of fatty acid binding protein, a marker of tubular cell inj

78 Further, the folding of fatty acid binding protein, a predominantly beta-sheet p

79 In addition to acrylodan-labeled fatty acid binding protein, a probe that detects unbound

80 was determined by measuring the fluorescent fatty acid-binding protein ADIFAB added to the external

81 (e.g., major urinary proteins in the liver, fatty acid binding proteins, adipose differentiation-rel

82 hormone sensitive lipase (HSL) and adipocyte fatty acid-binding protein (AFABP) form a physical compl

83 Adipocyte fatty acid-binding protein (AFABP/aP2) facilitates the i

84 hormone-sensitive lipase (HSL) and adipocyte fatty acid-binding protein (AFABP/aP2) form a physical c

85 Adipocyte fatty acid-binding protein (AFABP/aP2) forms a physical

86 In addition to atherosclerosis, these fatty acid binding proteins also exert a dramatic impact

87 ctivated receptors, Toll-like receptors, and fatty acid-binding proteins, also act as links between n

88 glyceride lipase, plasma membrane-associated fatty acid binding protein and AMPKgamma3 subunit protei

89 helial barrier integrity markers (intestinal fatty acid binding protein and zonulin-1 levels), solubl

90 Plasma intestinal fatty acid-binding protein and citrulline concentrations

91 relation between plasma levels of intestinal fatty acid-binding protein and citrulline.

92 diminished the expression of intestinal-type fatty acid-binding protein and lactate dehydrogenase (34

93 ion defects such as expression of intestinal fatty acid-binding protein and pancreatic trypsin.

94 The link between intestinal fatty acid-binding protein and plasma citrulline concent

95 se-associated lipocalin, IL-18, KIM-1, liver fatty acid binding protein, and albumin associated indep

96 -18, kidney injury molecule-1 (KIM-1), liver fatty acid binding protein, and albumin.

97 a levels of soluble CD14 (sCD14), intestinal fatty acid binding protein, and interleukin-6 by enzyme-

98 cyte injury, including troponins, heart-type fatty acid binding protein, and myosin light chain-1, ma

99 embrane and internal sites, by intracellular fatty acid binding proteins, and by enzymes in synthetic

100 g adipocyte differentiation-related protein, fatty acid-binding protein, and cathepsin E.

101 ylglycerol acyltransferase activities, CD36, fatty acid-binding protein, and fatty acid transport pro

102 , C/EBPalpha, C/EBPdelta, SREBP-1, epidermal fatty acid-binding protein, and SCD.

103 l marker genes such as tranferrin, epidermal fatty acid-binding protein, androgen-binding protein, an

104 The fatty acid binding proteins aP2 (fatty acid binding prot

105 The fatty acid-binding protein aP2 is a cytoplasmic lipid ch

106 measuring their ability to induce adipocyte fatty acid-binding protein (aP2) mRNA expression.

107 olved in lipid metabolism, such as adipocyte fatty acid-binding protein (aP2), lipoprotein lipase (LP

108 ated more lipid and expressed more adipocyte fatty acid-binding protein (aP2), peroxisome proliferato

109 -acid binding protein (L-FABP) and adipocyte fatty acid-binding protein (aP2), two established PPARga

110 BP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).

111 e in adipose tissue, driven by the adipocyte fatty acid-binding protein (aP2, also known as aFABP) pr

112 Adipocyte/macrophage fatty acid binding proteins, aP2 and mal1, act at the in

113 Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in

114 The adipocyte fatty-acid-binding protein, aP2, has an important role i

115 Fatty acid binding proteins are clearly important in reg

116 These fatty acid binding proteins are involved in the formatio

117 Fatty acid-binding proteins are cytosolic fatty acid cha

118 il gelatinase-associated lipocalin and liver fatty acid-binding protein associations with both defini

119 chain protein, low Abeta1-42, and high heart fatty acid-binding protein at baseline were related to f

120 reviously shown that regulation of the brain fatty acid-binding protein (B-FABP; FABP7) and glial fib

121 nts in ubiquitin (alphabeta-fold) intestinal fatty acid binding protein (beta-barrel) and carp parval

122 /EBPalpha, PPARgamma2, and adipose protein 2/fatty acid-binding protein by DEX, MIX, and insulin in 3

123 The expression of cutaneous fatty acid-binding protein (C-FABP) in prostate tissues

124 he adipocyte marker genes adipsin, adipocyte fatty acid-binding protein, C/EBPalpha, PPARgamma, and l

125 a and fibroblast growth factor 4, heart-type fatty acid binding protein, calcitonin, and tumor necros

126 l markers, the intestinal markers intestinal fatty acid binding protein, CDX1 and CDX2 were rarely ex

127 )-deficient (CFTR knockout, Cftr(tm1Unc-)TgN(fatty acid-binding protein)CFTR) and mutant (DeltaF508)

128 paxillin suggests that S100A7 and epidermal fatty acid binding protein colocalize in focal adhesion-

129 e studies indicate that S100A7 and epidermal fatty acid binding protein colocalize in the cytoplasm i

130 ulline</=12.2 mumol/L, and plasma intestinal fatty acid-binding protein concentration>/=355 pg/mL wer

131 nal fatty acid-binding protein), ILBP (ileal fatty acid-binding protein), CRABP I (cellular retinoic

132 This review will highlight recent studies on fatty acid binding protein-deficient models and several

133 an-shaped body, increasing the expression of Fatty acid binding protein (dFabp), or by administering

134 Mechanistically, epidermal fatty acid binding protein (E-FABP) was significantly up

135 report the identification of the epithelial fatty acid-binding protein (E-FABP) as a molecular targe

136 Epidermal fatty acid-binding protein, E-FABP, a lipid chaperone, h

137 Intestinal fatty acid-binding protein elevation at admission to the

138 R(2) = 0.25) expressions and with changes in fatty acid binding protein expression (R(2) = 0.33).

139 auged by significant reduction of intestinal fatty acid-binding protein expression.

140 /EBPalpha, PPARgamma2, and adipose protein 2/fatty acid-binding protein expression; however, PPARgamm

141 approaches, and the levels of CSF heart-type fatty acid binding protein (FABP) and 12 other correlate

142 The role of cytosolic fatty acid binding protein (FABP) in cellular fatty acid

143 we reported that a native Fasciola hepatica fatty acid binding protein (FABP) termed Fh12 is a power

144 Fatty acid binding proteins (FABP) are involved in fatty

145 dquarters, as well as muscle plasma membrane fatty acid-binding protein (FABP(PM)) content of lean (n

146 The adipocyte fatty acid-binding protein (FABP) aP2 is expressed by ad

147 ng protein (A-Fabp) and other members of the fatty acid-binding protein (Fabp) family as interaction

148 g protein (LFABP), an atypical member of the fatty acid-binding protein (FABP) family that binds more

149 ein family and Z found to be a member of the fatty acid-binding protein (FABP) family.

150 sis is mediated, in part, via interaction of fatty acid-binding protein (FABP) with hormone-sensitive

151 adipocytes expressed adiponectin, perilipin, fatty acid-binding protein (FABP), leptin, C/EBPalpha, a

152 essing progastrin (PG) in intestinal mucosa (fatty acid-binding protein (Fabp)-PG mice) are at an inc

153 Fatty acid-binding proteins (FABP) are known central reg

154 ems have demonstrated a role for cytoplasmic fatty acid-binding proteins (FABP) in lipid metabolism,

155 The enterocyte expresses two fatty acid-binding proteins (FABP), intestinal FABP (IFA

156 Fatty-acid binding proteins (FABP) and myeloperoxidases

157 The fatty acid binding proteins aP2 (fatty acid binding protein [FABP]-4) and mal1 (FABP5) ar

158 ding those for the anticipated targets liver fatty acid binding protein (Fabp1) and lactase-phlorizin

159 Serum liver-type fatty acid binding protein (FABP1) early (day 1) or late

160 Here, we demonstrate that the heart-type fatty acid-binding protein, FABP3, is essential for cold

161 Targeted deletion of the murine fatty acid binding protein (FABP4/aP2) uncouples obesity

162 demonstrated that deletion of the adipocyte fatty acid-binding protein (FABP4/aP2) uncouples obesity

163 pite the abundant expression of adipose-type fatty acid-binding protein, FABP4 (also known as aP2).

164 onectin, perilipin, and the adipose-specific fatty acid-binding protein, FABP4/aP2.

165 A-binding proteins CRABP1 and CRABP2 and the fatty acid-binding protein FABP5 are dynamically express

166 We show further that the fatty acid-binding protein FABP5 controls both of these

167 The fatty acid-binding protein FABP5 shuttles ligands from t

168 The astrocyte brain fatty acid binding protein (Fabp7) has previously been s

169 In mammals, serum albumin, fatty acid binding proteins (FABPs) and organic anion tr

170 Three fatty acid binding proteins (FABPs) known to be expresse

171 netic analysis of avian and other vertebrate fatty acid binding proteins (FABPs) supported the hypoth

172 Fatty acid binding proteins (FABPs), in particular FABP5

173 retinoic acid-binding proteins (CRABPs) and fatty acid binding proteins (FABPs).

174 Fatty acid-binding proteins (FABPs) act as intracellular

175 tricted coexpression of adipocyte/macrophage fatty acid-binding proteins (FABPs) aP2 (FABP4) and mal1

176 Cytoplasmic fatty acid-binding proteins (FABPs) are a family of prot

177 Fatty acid-binding proteins (FABPs) are a widely express

178 Fatty acid-binding proteins (FABPs) are abundant intrace

179 The intracellular fatty acid-binding proteins (FABPs) are abundantly expre

180 Fatty acid-binding proteins (FABPs) are cytosolic fatty

181 Fatty acid-binding proteins (FABPs) are intracellular pr

182 Recently, we identified fatty acid-binding proteins (FABPs) as intracellular NAE

183 Intracellular fatty acid-binding proteins (FABPs) may differentially b

184 cular homeostasis and are bound by cytosolic fatty acid-binding proteins (FABPs) with K(d) values of

185 llular lipid-binding proteins, including the fatty acid-binding proteins (FABPs), can chaperone ligan

186 tif that suggest it is a novel member of the fatty acid-binding protein family and may thus transport

187 inity drug-like compound and a member of the fatty acid-binding protein family.

188 enesis, such as lipid droplet morphology and fatty acid binding protein (FAPB)-4 expression, were not

189 In vitro, these proteins are fatty-acid-binding proteins (FAPs).

190 ticle that a single i.p. injection of 15 mug fatty acid binding protein from Fasciola hepatica (Fh12)

191 creation of pharmacological agents to modify fatty acid binding protein function will provide tissue

192 the control of elements from the intestinal fatty acid binding protein gene (Fabpi).

193 ed a TE-gene chimeric transcript involving a fatty acid-binding protein gene (LTR2-FABP7), normally e

194 Heart-type fatty acid binding protein (H-FABP) is a cytosolic prote

195 Heart fatty acid binding protein (H-FABP) is expressed in neur

196 n basic protein (MBP), S100B, and heart-type fatty acid binding protein (H-FABP) were measured in CSF

197 We addressed this issue using heart fatty acid-binding protein (H-FABP) gene-ablated mice.

198 e if a high-performance assay for heart-type fatty acid-binding protein (H-FABP) has a role in predic

199 librium unfolding behavior of the intestinal fatty acid-binding protein has been investigated by (19)

200 Heart type fatty acid binding protein (HFABP) as an early marker of

201 The human intestinal fatty acid binding protein (I-FABP) belongs to a family

202 t microbial translocation marker (intestinal fatty acid binding protein (I-FABP)) were measured in 25

203 The enterocyte-specific protein, intestinal fatty acid binding protein (I-FABP), is detectable in se

204 We measured plasma intestinal fatty acid binding protein (I-FABP), soluble CD14 (sCD14

205 Analogous to that in the intestinal fatty acid binding protein (I-FABP), we hypothesize that

206 (LBP), soluble CD14 (sCD14), and intestinal fatty acid binding protein (I-FABP).

207 e (LPS), endotoxin core antibody, intestinal fatty acid-binding protein (I-FABP), soluble CD14 (sCD14

208 determinants of plasma levels of intestinal fatty acid-binding protein (I-FABP/FABP2), a marker of g

209 ctor [TNF]), enterocyte turnover (intestinal fatty acid binding protein [I-FABP]), lipopolysaccharide

210 Intestinal fatty acid binding protein (IFABP) appears to interact d

211 s problem has been simplified for intestinal fatty acid binding protein (IFABP) by incorporating fluo

212 Rat intestinal fatty acid binding protein (IFABP) displays an intermedi

213 Intestinal fatty acid binding protein (IFABP) is a member of the li

214 The intestinal fatty acid binding protein (IFABP) is a small (15 kDa) p

215 The intestinal fatty acid binding protein (IFABP) is composed of two be

216 The rat intestinal fatty acid binding protein (IFABP) primarily comprises t

217 ctional all-beta sheet variant of intestinal fatty acid binding protein (IFABP) that was generated by

218 ents have been carried out on the intestinal fatty acid binding protein (IFABP) to study microsecond

219 of 4-(19)F-phenylalanine into the intestinal fatty acid binding protein (IFABP), a protein composed o

220 alpha-lactalbumin, cytochrome c, intestinal fatty acid binding protein (IFABP), and myoglobin.

221 (pCFTR) cDNA under control of the intestinal fatty acid-binding protein (iFABP) promoter would allevi

222 igration inhibitory factor (MIF), intestinal fatty acid-binding protein (IFABP), and proinflammatory

223 valuated the usefulness of plasma intestinal fatty-acid binding protein (IFABP) levels in the early i

224 rkers (LPS, soluble CD14 [sCD14], intestinal fatty acid-binding protein [iFABP], and endotoxin core I

225 eta-sheet proteins, namely IFABP (intestinal fatty acid-binding protein), ILBP (ileal fatty acid-bind

226 identify factors associated with intestinal fatty acid-binding protein in critically ill patients.

227 neral protein interaction domain utilized by fatty acid-binding proteins in regulatory control of lip

228 had higher plasma levels of LPS, intestinal fatty acid binding protein (indicating enterocyte death)

229 Fatty acid binding proteins integrate metabolic and immu

230 , we show that the test protein, human liver fatty acid binding protein, interacts reversibly and per

231 Epidermal fatty acid binding protein is also overexpressed in psor

232 The intestinal fatty acid binding protein is composed of two beta-sheet

233 The intestinal fatty acid binding protein is one of a family of protein

234 The portal region of fatty acid binding proteins is hypothesized to function

235 Intestinal fatty acid-binding protein is a marker of enterocyte dam

236 Heart-type fatty acid-binding protein is released into the circulat

237 ry molecule-1 (KIM-1), IL-18, and liver-type fatty acid binding protein (L-FABP) from 1304 deceased d

238 Liver fatty acid binding protein (L-FABP) has been proposed to

239 Although liver fatty acid binding protein (L-FABP) is known to bind not

240 ry molecule-1 (KIM-1), IL-18, and liver-type fatty acid binding protein (L-FABP) were measured in spo

241 Liver fatty acid binding protein (L-FABP), a cytosolic protein

242 kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), and albumin differe

243 kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), and interleukin (IL

244 ith proteins--including serum albumin, liver fatty acid binding proteins (L-FABP), and organic anion

245 on of the two lipid transfer proteins, liver fatty acid-binding protein (L-FABP) and MTP, which coope

246 was addressed in cells expressing liver-type fatty acid-binding protein (L-FABP) by real time multiph

247 Whereas the role of liver fatty acid-binding protein (L-FABP) in the uptake, trans

248 Liver fatty acid-binding protein (L-Fabp) is an abundant cytos

249 Although liver fatty acid-binding protein (L-FABP) is an important bind

250 The possibility that the liver fatty acid-binding protein (L-FABP) may function in this

251 Liver fatty acid-binding protein (L-Fabp) regulates murine hep

252 Here we show that liver fatty acid-binding protein (L-Fabp), an abundant cytosol

253 luorescence colocalization showed that liver fatty acid-binding protein (L-FABP; binds LCFA-CoA as we

254 he bands contained both liver and intestinal fatty acid-binding proteins (L- and I-FABP) as well as f

255 gonucleotide and induced expression of liver fatty-acid binding protein (L-FABP) and adipocyte fatty

256 lipocalin [NGAL], interleukin [IL]-18, liver fatty acid-binding protein [L-FABP], and kidney injury m

257 cells and demonstrated that expression of a fatty acid-binding protein, L-FABP, specifically enhance

258 A7 expression appears to stabilize epidermal fatty acid binding protein level, and vice versa.

259 Liver fatty acid-binding protein (LFABP) is a 14 kDa cytosolic

260 Rat liver fatty acid-binding protein (LFABP) is distinctive among

261 patic cathepsin B and lower amounts of liver fatty acid-binding protein (LFABP) than their wildtype l

262 re used to probe ligand binding to rat liver fatty acid-binding protein (LFABP), an atypical member o

263 Liver fatty acid-binding protein (LFABP; FABP1) is expressed b

264 A second fatty acid-binding protein, mal1, also is expressed in a

265 binding protein-deficient models and several fatty acid binding protein-mediated pathways specificall

266 ree test cases: one complex involving muscle fatty acid-binding protein (mFABP) and two complexes inv

267 royl-CoA desaturase-1 (SCD-1), and epidermal fatty acid-binding protein more than rat serum alone.

268 glycogen phosphorylase), transport proteins (fatty acid-binding protein, myoglobin and somatic cytoch

269 ncluded glutathione S-transferase (P<0.001), fatty acid binding protein (P<0.001), and alanine aminop

270 These included fatty acid binding protein, phospholipid binding protein

271 Heart-type fatty acid-binding protein predicts long-term mortality

272 ed CFTR(-/-) mice bearing a transgene with a fatty acid binding protein promoter driving expression o

273 cyclin D1 under the control of the rat liver fatty acid binding protein promoter.

274 e, generated by utilizing the rat intestinal fatty acid-binding protein promoter (Fabpi), overexpress

275 Nucleotides -596 to +21 of the rat liver fatty acid-binding protein promoter were used to direct

276 cell (CD2) or a small intestinal enterocyte (fatty acid-binding protein) promoter have markedly incre

277 s glutathione S-transferase, LDH, heart-type fatty acid binding protein, redox-active iron, IL-18, an

278 ase, lactate dehydrogenase (LDH), heart-type fatty acid binding protein, redox-active iron, interleuk

279 Furthermore, expression of the liver fatty acid binding protein reduced the availability of b

280 site-specific mutants of the rat intestinal fatty acid binding protein (rI-FABP) with acrylodan.

281 mics around a beta-barrel protein, rat liver fatty acid-binding protein (rLFABP), to reveal the effec

282 the N and C termini that is homologous to a fatty acid-binding protein signature.

283 mucosal dysfunction markers intestinal-type fatty acid-binding protein, soluble suppression of tumor

284 s a marked delay in expression of intestinal fatty acid binding protein, suggesting a role for PTK6 i

285 The FakBs are fatty acid binding proteins that exchange bound fatty ac

286 ng protein (ALBP or aP2) is an intracellular fatty acid-binding protein that is found in adipocytes a

287 g cells with ADIFAB, a fluorescently labeled fatty acid-binding protein that is used to measure unbou

288 epatic lipase, endothelial lipase, the liver fatty acid-binding protein, the beta3-adrenergic recepto

289 wever, with BSA present to mimic cytoplasmic fatty acid-binding proteins, the mitochondrial populatio

290 ar RA binding protein type II (CRABP-II) and fatty acid binding protein type 5 in adipocytes and skel

291 kidney injury molecule-1, urinary liver-type fatty acid binding protein, urinary interleukin-18, and

292 (+/+) cells, and hepatic expression of liver fatty acid binding protein was lower in p110-alpha(-/-)

293 The GI mucosal intestinal fatty acid-binding protein was decreased after transplan

294 FA, ADIFAB (acrylodan-labeled rat intestinal fatty acid-binding protein), was microinjected into isol

295 Blood citrulline and intestinal fatty acid binding protein were determined as biomarkers

296 Serum levels of troponin T and heart-type fatty acid binding protein were increased (P < 0.05) aft

297 osphorylated tau, alpha-synuclein, and heart fatty acid-binding protein were quantified by 2 blinded

298 chain protein, low Abeta1-42, and high heart fatty acid-binding protein were related to future PDD, p

299 transport or storage (adipophilin and liver fatty acid-binding protein) were also activated by agoni

300 like albumin in plasma and interstitium and Fatty Acid-Binding Proteins within endothelium and cardi